Compound 32-134D inhibited the expression of CNTF, CTF, IL-6, IL-9, IL-11, IL-17A, IL-22, and OSM (P < 0.05; Figure 6 and Supplemental Table 3), which are all known to activate JAK/STAT3 signaling, leading to HCC progression (62–68). This evidence concerns the gene IL9 and hepatocellular carcinoma.